Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies

被引：4
|
作者：
Gressens, Simon B. [1 ]
Wiedemann, Aurelie [2 ,4 ]
Dechenaud, Marie [2 ]
Dupuis, Jehan [3 ]
Gallien, Sebastien [1 ,4 ]
Melica, Giovanna [1 ,4 ]
Haioun, Corinne [3 ,4 ]
Lemonnier, Francois [3 ,4 ]
Levy, Yves [1 ,2 ]
机构：
[1] Univ Paris Est Creteil, Hop Univ Henri Mondor, AP HP, Infect Dis & Immunol Dept, Creteil, France
[2] Univ Paris Est Creteil, Vaccine Res Inst, Fac Med, Team 16,INSERM U955, Creteil, France
[3] Grp Hosp Univ Chenevier Mondor, Serv Unite Hemopathies Lymphoides, IAP HP, F-94010 Creteil, France
[4] Univ Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France
来源：
VACCINE | 2023年 / 41卷 / 09期
关键词：
Third dose; COVID-19; Immunocompromised; Vaccine; T cell responses; Hematological malignancies; SARS-COV-2; IMMUNITY;
D O I：
10.1016/j.vaccine.2023.01.064
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Patients receiving anti-CD20 antibodies showed limited efficacy of a booster dose of BNT162b2. Patients with lymphomas combine such immunotherapies with cytotoxic chemotherapies that could result in an even greater alteration of the immune response to vaccination. We report here the impact of a third vac-cine dose on T cell specific responses in a small cohort of patients treated in our center by anti-CD20 ther-apies and cytotoxic chemotherapies for lymphoid malignancies. Our results showed that a third dose in these severely immune suppressed patients could improve the expansion on CD4+Th1+T cell responses while the effect CD8 + T cell responses was marginal. (c) 2023 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1550 / 1553
页数：4
相关论文
共 50 条
  • [21] Reduced Titers of Circulating Anti-SARS-CoV-2 Antibodies and Risk of COVID-19 Infection in Healthcare Workers during the Nine Months after Immunization with the BNT162b2 mRNA Vaccine
    Coppeta, Luca
    Ferrari, Cristiana
    Somma, Giuseppina
    Mazza, Andrea
    D'Ancona, Umberto
    Marcuccilli, Fabbio
    Grelli, Sandro
    Aurilio, Marco Trabucco
    Pietroiusti, Antonio
    Magrini, Andrea
    Rizza, Stefano
    VACCINES, 2022, 10 (02)
  • [22] Anti-SARS-CoV-2 RBD IgG responses in convalescent versus naive BNT162b2 vaccine recipients
    Azzi, Lorenzo
    Focosi, Daniele
    Dentali, Francesco
    Baj, Andreina
    Maggi, Fabrizio
    VACCINE, 2021, 39 (18) : 2489 - 2490
  • [23] Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients
    Yanay, Noa Berar
    Freiman, Sarit
    Shapira, Ma'anit
    Wishahi, Samar
    Hamze, Munir
    Elhaj, Mohamad
    Zaher, Maha
    Armaly, Zaher
    KIDNEY INTERNATIONAL, 2021, 99 (06) : 1496 - 1498
  • [24] Effect of a Third Dose of SARS-CoV-2 mRNA BNT162b2 Vaccine on Humoral and Cellular Responses and Serum Anti-HLA Antibodies in Kidney Transplant Recipients
    Cassaniti, Irene
    Gregorini, Marilena
    Bergami, Federica
    Arena, Francesca
    Sammartino, Jose Camilla
    Percivalle, Elena
    Soleymaninejadian, Ehsan
    Abelli, Massimo
    Ticozzelli, Elena
    Nocco, Angela
    Minero, Francesca
    Pattonieri, Eleonora Francesca
    Lilleri, Daniele
    Rampino, Teresa
    Baldanti, Fausto
    VACCINES, 2022, 10 (06)
  • [25] Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization
    Salvagno, Gian Luca
    Lippi, Giuseppe
    VACCINES, 2022, 10 (06)
  • [26] Intensity and Dynamics of Anti-SARS-CoV-2 Immune Responses after BNT162b2 mRNA Vaccination: Implications for Public Health Vaccination Strategies
    Speletas, Matthaios
    Voulgaridi, Ioanna
    Sarrou, Styliani
    Dadouli, Aikaterini
    Mouchtouri, Varvara A.
    Nikoulis, Dimitrios J.
    Tsakona, Maria
    Kyritsi, Maria A.
    Peristeri, Athanasia-Marina
    Avakian, Ioanna
    Nasika, Asimina
    Fragkou, Paraskevi C.
    Moschopoulos, Charalampos D.
    Zoubouneli, Stamatia
    Onoufriadis, Ilias
    Anagnostopoulos, Lemonia
    Matziri, Alexia
    Papadamou, Georgia
    Theodoridou, Aikaterini
    Tsiodras, Sotirios
    Hadjichristodoulou, Christos
    VACCINES, 2022, 10 (02)
  • [27] Effect of anti-SARS-CoV-2 BNT162b2 mRNA vaccination on thrombin generation in children with inflammatory bowel disease
    Stercel, Vivien
    Loczi, Linda
    Kadenczki, Orsolya
    Nemes, Eva
    Nagy, Bela
    Hodossy-Takacs, Rebeka
    Szabo, Attila adam
    Fagyas, Miklos
    Kappelmayer, Janos
    Szabo, Tamas
    Bagoly, Zsuzsa
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [28] SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents
    Fenioux, Charlotte
    Teixeira, Luis
    Fourati, Slim
    Melica, Giovanna
    Lelievre, Jean Daniel
    Gallien, Sebastien
    Zalcman, Gerard
    Pawlotsky, Jean Michel
    Tournigand, Christophe
    JAMA ONCOLOGY, 2022, 8 (04) : 612 - 617
  • [29] Humoral Response after Three Doses of mRNA-1273 or BNT162b2 SARS-CoV-2 Vaccines in Hemodialysis Patients
    Jesus Broseta, Jose
    Rodriguez-Espinosa, Diana
    Cuadrado, Elena
    Rodriguez, Nestor
    Luis Bedini, Jose
    Maduell, Francisco
    VACCINES, 2022, 10 (04)
  • [30] Humoral Response to BNT162b2 mRNA SARS-CoV-2 Vaccine in Patients with Nondialysis Chronic Kidney Disease
    Kervella, Delphine
    Braud, Pierre
    Garandeau, Claire
    Phelizot, Celine
    Ambrosi, Xavier
    Blancho, Gilles
    Hourmant, Maryvonne
    Figueres, Lucile
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 16 (12): : 1872 - 1874
12345